# A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer

> **NCT06344351** · PHASE1 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 27 (actual)

## Conditions studied

- Advanced Malignant Neoplasm

## Interventions

- **DRUG:** TQB3006 tablets

## Key facts

- **NCT ID:** NCT06344351
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-25
- **Primary completion:** 2025-05-20
- **Final completion:** 2025-05-20
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06344351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06344351, "A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06344351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*